Tag: Radionetics Oncology

Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

– Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million– Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein…

Read More Read More

Radionetics Oncology has filed a notice of an exempt offering of securities to raise $68,711,758.00 in New Equity Investment.

Radionetics Oncology has filed a notice of an exempt offering of securities to raise $68,711,758.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Radionetics Oncology is raising $68,711,758.00 in new funding. Sources indicate that as part of senior management Interim Chief Operating Officer, Brett Ewald played a key…

Read More Read More